Feed Preview
Autoimmune Disease Therapy
In autoimmune diseases, the immune system responds and attacks self-antigens and damages or impairs the function of the tissues. The treatment for autoimmune diseases often involves immunosuppressive agents, but newer treatments are being investigated. Discover the latest research on autoimmune disease therapy here.
Top 20 most recent papers
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet OncologyNovember 27, 2019
Peter SchmidIMpassion130 Investigators
57
1
Treg cell-based therapies: challenges and perspectives
Nature Reviews. ImmunologyDecember 6, 2019
Caroline RaffinJeffrey A. Bluestone
American Society of Hematology 2019 guidelines for immune thrombocytopenia
Blood AdvancesDecember 4, 2019
Cindy E NeunertSara K Vesely
1
11
Human Tolerogenic Dendritic Cells Regulate Immune Responses through Lactate Synthesis
Cell MetabolismDecember 3, 2019
Eros MarínAurélie Moreau
15
Short and Long Term Clinical and Immunologic Follow up after Bone Marrow Mesenchymal Stromal Cell Therapy in Progressive Multiple Sclerosis-A Phase I Study
Journal of Clinical MedicineDecember 2, 2019
Ellen IacobaeusKatarina Le Blanc
Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck
JAMA Otolaryngology-- Head & Neck SurgeryDecember 5, 2019
Samantha TamNeil D Gross
5
Evolving story of autoantibodies in systemic lupus erythematosus
Journal of AutoimmunityDecember 3, 2019
David S Pisetsky
Protein C-ets-2 epigenetically suppresses TLRs-induced interleukin 6 production in macrophages
Biochemical and Biophysical Research CommunicationsDecember 3, 2019
Jun ZhaoJi-Feng Feng
The Balance in T Follicular Helper Cell Subsets Is Altered in Neuromyelitis Optica Spectrum Disorder Patients and Restored by Rituximab
Frontiers in ImmunologyNovember 19, 2019
Philippe NicolasRomain Marignier
Anti-MOG autoantibodies pathogenicity in children and macaques demyelinating diseases
Journal of NeuroinflammationNovember 30, 2019
Che SergueraKumaran Deiva
Modulation of bioavailability of proinflammatory cytokines produced by myeloid cells
Seminars in Arthritis and RheumatismNovember 30, 2019
Maxim A NosenkoSergei A. Nedospasov
Interleukin-35 Regulates Immune Microenvironment of Autoimmune Hepatitis Through Inducing the Expansion of Myeloid-Derived Suppressor Cells
Frontiers in ImmunologyNovember 7, 2019
Min LianXiong Ma
Ocular myasthenia gravis: updates on an elusive target
Current Opinion in NeurologyNovember 27, 2019
Andrew T MelsonMichael S. Lee
Fostamatinib disodium hexahydrate: a novel treatment for adult immune thrombocytopenia
The American Journal of Managed CareNovember 1, 2019
Ali McBrideAmit R Mehta
Concurrent anti-PM-Scl antibody-associated systemic sclerosis and inclusion body myositis - report of two cases and review of the literature
Seminars in Arthritis and RheumatismNovember 16, 2019
Soumya Chatterjee, Richard A Prayson
Tuning the performance of CAR T cell immunotherapies
BMC BiotechnologyNovember 29, 2019
Noah H RichardsonMarko Z Radic
Emerging Connections of S1P-Metabolizing Enzymes with Host Defense and Immunity During Virus Infections
VirusesNovember 27, 2019
Jennifer J WolfBumsuk Hahm
Interleukin-17 and lupus: enough to be a target? For which patients?
LupusDecember 2, 2019
Marie Robert, Pierre Miossec
Intravenous immunoglobulin (IVIg) acts directly on conventional T cells to suppress T cell receptor signaling
Biochemical and Biophysical Research CommunicationsNovember 29, 2019
Ayane HoriSeiji Kawamoto
Mesenchymal Stem Cells: Allogeneic MSC May Be Immunosuppressive but Autologous MSC Are Dysfunctional in Lupus Patients
Frontiers in Cell and Developmental BiologyNovember 15, 2019
Rui-Juan ChengTony N Marion